Literature DB >> 25406627

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.

Ray R Zhang1, Kelli B Pointer, John S Kuo, Robert J Dempsey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25406627     DOI： 10.1227/NEU.0000000000000580

Source DB:  PubMed          Journal:  Neurosurgery        ISSN： 0148-396X            Impact factor:   4.654


× No keyword cloud information.
  4 in total

Review 1.  Recent advances and future of immunotherapy for glioblastoma.

Authors:  Neha Kamran; Alexandra Calinescu; Marianela Candolfi; Mayuri Chandran; Yohei Mineharu; Antonela S Asad; Carl Koschmann; Felipe J Nunez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2016-07-27       Impact factor: 4.388

2.  Trophinin-associated protein expression correlates with shorter survival of patients with glioma: a study based on multiple data fusion analysis.

Authors:  Yong Sun; Zhen Dong Liu; Run Ze Liu; Xiao Yu Lian; Xing Bo Cheng; Yu Long Jia; Bin Feng Liu; Yan Zheng Gao; Xinjun Wang
Journal:  Mol Biol Rep       Date:  2022-06-16       Impact factor: 2.742

3.  A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme.

Authors:  Hayley Nehoff; Neha N Parayath; Melanie J McConnell; Sebastien Taurin; Khaled Greish
Journal:  Oncotarget       Date:  2015-11-10

4.  MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma.

Authors:  Qi Liu; Qiyuan Bao; Yiqi Xu; Yucheng Fu; Zhijian Jin; Jun Wang; Weibin Zhang; Yuhui Shen
Journal:  Front Cell Dev Biol       Date:  2021-06-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.